A Multicenter, Randomized, Double blind, Parallel, Two arm, Active Controlled phase II study to evaluate the Efficacy and Safety of Fixed Drug Combination (FDC) of Minoxidil (5%) and Adenosine (1%) topical solution in comparison to Minoxidil (5%) topical solution in the treatment of Hair Loss in subjects with Androgenetic Alopecia.

Dr Reddys Laboratories Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方: Dr Reddys Laboratories Limited

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Male or female subjects between 18 â?? 45 years of age, with a clinical diagnosis of Androgenetic Alopecia (AGA).
•2. Male subjects exhibiting male pattern hair loss as described by Norwood-Hamilton Scale III vertex to V OR Female subjects exhibiting female pattern hair loss as described by Sinclair classification grade 2 to grade 4.
•3. Subjects willing to provide written informed consent and comply with study instructions for its duration.
•4. Subjects willing to maintain same hair style and colour through-out the study.
•5. Females of child-bearing potential should have a negative urine pregnancy test prior to beginning therapy and agree to use adequate birth control during the study (acceptable methods include hormonal contraception maintained for a period of 3 months prior to the study and persisting through the study period, intrauterine device, barrier or abstinence).

排除标准

•1. Subjects with known hypersensitivity to Minoxidil or Adenosine or any of the ingredients of the test drugs or tattoo ink.
•2. Females who are pregnant, breast feeding, or planning a pregnancy during the proposed study period.
•3. Any dermatological disorders of the scalp with the possibility of interfering with the clinical study related evaluation methods, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars or scalp atrophy.
•4. Active hair loss or history within the past 3 months including diffuse telogen effluvium, alopecia areata, scarring alopecia.
•5. Any severe, acute or chronic medical condition that may lead to hair loss or interfere with the interpretation of trial results.
•6. Subjects who had hair transplant surgery, hair weaves or non-breathable wigs and hair bonding.
•7. Use of any anti-hair loss treatment within the last 6 months prior to the screening visit including Minoxidil, Finasteride, Dutasteride or similar products.
•8. Current use or history of use of systemic treatment (drugs or dietary supplement) taken for more than 2 consecutive weeks interfering with the study product or evaluations (Beta blockers, Cimetidine, Diazoxid, Isotretinoin, corticosteroids, Vitamin A intake above 10000 IU per day) within past 3 months.
•9. Current use or history of use of local treatment (drug or cosmetically) on scalp interfering with the study product or evaluation (topical corticosteroids, Aminexil, Minoxidil, medicated shampoos, topical estrogen, topical Ketoconazole) within past 4 weeks.
•10. Enrolled in any other investigational medication study currently, or within the last 6 months.
•11. History of undergoing chemotherapy or receiving cytotoxic agents or radiation and/or laser/surgical therapy of the scalp within past 6 months.
•12. Subjects with clinically significant cardiovascular, liver, lung, neurologic, renal or psychiatric disorder, or clinically significant laboratory abnormalities (if laboratory values exceed the threshold limits set out for this study, the approval of Medical Monitor should be taken into consideration before randomizing the subject).
•13. Subjects with a history or examination findings of alcohol dependence, alcohol or drug abuse or suspected abuse.

研究者

发起方

Dr Reddys Laboratories Limited

相似试验

招募中

3 期

Phase III Global Study to Assess the Efficacy and Safety of Bevacizumab compared to Avastin in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with Stage IIIB/IV Lung Cancer

CTRI/2021/10/037247CURATEQ BIOLOGICS PRIVATE LIMITED India

进行中（未招募）

1 期

A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC).ewly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 20.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-005618-16-HUCuraTeQ Biologics Private Limited648

进行中（未招募）

不适用

A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 760564 in Adult Patients with Rheumatoid Arthritis Receiving Methotrexate - RACERMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid Arthritis

EUCTR2006-002216-10-HUProcter & Gamble Pharmaceuticals270

进行中（未招募）

不适用

EUCTR2006-002216-10-NLProcter & Gamble Pharmaceuticals270

进行中（未招募）

不适用

EUCTR2006-002216-10-CZProcter & Gamble Pharmaceuticals270